News Reduction of share capital Staff April 20, 2022 Please read the full announcement in the attached PDF Attachment 2022_12_Reduction_of_share_capital Iframe sync Post navigation Previous: Clover’s Efficacy Data in Previously-Infected Individuals is Published in Lancet Infectious DiseaseNext: Otonomy Reports Positive Top-Line Results from Phase 2a Clinical Trial of OTO-413 in Patients with Hearing Loss More Stories Diagnostics EHR Healthcare News Pharmaceutical Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope Staff January 11, 2026 Clinical Trial DNA News Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response Staff January 11, 2026 Cancer Clinical Trial Healthcare News Pharmaceutical Pregnancy Best GLP-1 Weight Loss Shot (2026): Direct Meds Reviews Prescription Access Pathways as New GLP-1 Formats Expand Staff January 11, 2026
